For FSHD, it is encouraging that a number of biotech companies (Avidity Biosciences, Dyne Therapeutics, Arrowhead Pharmaceuticals, miRecule, and Armatusbio) are actively developing DUX4-targeting oligonucleotide therapeutics for FSHD. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.